Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy

Autoimmunity Reviews

Volumn 10, Issue 5, 2011, Pages 267-275

  Wei, Jun ^a   Bhattacharyya, Swati ^a   Tourtellotte, Warren G ^a   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Collagen; Fibroblast; Fibrosis; Systemic sclerosis; TGF ; Wnt

Indexed keywords

ABELSON KINASE; CATENIN; EARLY GROWTH RESPONSE FACTOR; FIBRILLIN 1; INTERFERON; LIPID; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ADIPOCYTE; CELL ACTIVATION; CELL DAMAGE; CELL DIFFERENTIATION; CELL FATE; CELL TYPE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TARGETING; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROBLAST; FIBROSIS; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOXIA; LOSS OF FUNCTION MUTATION; LUNG FIBROSIS; MESENCHYME CELL; MYOFIBROBLAST; PATHOGENESIS; PERICYTE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ADIPOCYTES; ANIMALS; ANOXIA; BETA CATENIN; BIOLOGICAL MARKERS; CELL TRANSDIFFERENTIATION; EPITHELIAL CELLS; FIBROBLASTS; FIBROSIS; HUMANS; MICE; MICROFILAMENT PROTEINS; MOLECULAR TARGETED THERAPY; PERICYTES; PPAR GAMMA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS;

EID: 79952037889     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.09.015     Document Type: Review

References (68)

1. Leroy E.C. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972, 135:1351-1362.
2. LeRoy E.C. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974, 54:880-889.
3. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
4. Abraham D.J., Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595.
5. Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann Med 2007, 39:42-53.
6. Pannu J., Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 2004, 16:739-745.
7. Beutler B.A. TLRs and innate immunity. Blood Feb 12 2009, 113(7):1399-1407.
8. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med Nov 2007, 13(11):1324-1332. [Epub 2007 Oct 21].
9. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol Feb 2007, 19(1):3-10. [Epub 2007 Feb 1].
10. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005, 7:156-162.
11. Ihn H., Yamane K., Kubo M., Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001, 44:474-480.
12. Castelino F, Varga J. Interstitial lung disease in the connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther; 2010;12(4):213.
13. Ishida W., Mori Y., Lakos G., Sun L., Shan F., Bowes S., et al. Intracellular TGF-beta receptor blockade abrogates Smad- dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 2006, 126:1733-1744.
14. Pannu J., Gardner H., Shearstone J.R., Smith E., Trojanowska M. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: a model of scleroderma. Arthritis Rheum 2006, 54:3011-3021.
15. Chen Y., Shi-wen X., Eastwood M., Black C.M., Denton C.P., Leask A., et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006, 54:1309-1316.
16. Gardner H., Shearstone J.R., Bandaru R., Crowell T., Lynes M., Trojanowska M., et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006, 54:1961-1973.
17. Whitfield M.L., Finlay D.R., Murray J.I., Troyanskaya O.G., Chi J.T., Pergamenschikov A., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100:12319-12324.
18. Tan F.K., Zhou X., Mayes M.D., Gourh P., Guo X., Marcum C., et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) Jun 2006, 45(6):694-702. [Epub 2006 Jan 17].
19. Kim D., Peck A., Santer D., Patole P., Schwartz S.M., Molitor J.A., et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum Jul 2008, 58(7):2163-2173.
20. York M.R., Nagai T., Mangini A.J., Lemaire R., van Seventer J.M., Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum Mar 2007, 56(3):1010-20. [Erratum in: Arthritis Rheum. 2007 May;56(5):1675].
21. Duan H., Fleming J., Pritchard D.K., Amon L.M., Xue J., Arnett H.A., et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum May 2008, 58(5):1465-1474.
22. Dieudé P., Guedj M., Wipff J., Avouac J., Fajardy I., Diot E., et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum Jan 2009, 60(1):225-233.
23. Varga J.A., Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am Feb 2008, 34(1):115-143. [vii].
24. Chen S.J., Yuan W., Lo S., Trojanowska M., Varga J. Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol Jun 2000, 183(3):381-392.
25. Chen S.J., Yuan W., Mori Y., Levenson A., Trojanowska M., Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol Jan 1999, 112(1):49-57.
26. Ghosh A.K., Yuan W., Mori Y., Varga J. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene Jul 20 2000, 19(31):3546-3555.
27. Ghosh A.K., Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol Dec 2007, 213(3):663-671. [Review].
28. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum Jul 2002, 46(7):1703-1713. [Review. No abstract available].
29. Ihn H., Yamane K., Asano Y., Jinnin M., Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) Feb 2006, 45(2):157-165. [Epub 2005 Nov 30].
30. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest Jan 2004, 113(2):253-264.
31. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
32. Bhattacharyya S., Ishida W., Wu M., Wilkes M., Mori Y., Hinchcliff M., et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene Mar 12 2009, 28(10):1285-1297. [Epub 2009 Jan 19].
33. Chen S.J., Ning H., Ishida W., Sodin-Semrl S., Takagawa S., Mori Y., et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006, 281:21183-21197.
34. Yu J., de Belle I., Liang H., Adamson E.D. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr-1 in prostate cells, leading to divergent responses. Mol Cell 2004, 15:83-94.
35. Wu M., Melichian D.S., de la Garza M., Gruner K., Bhattacharyya S., Barr L., et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol Sep 2009, 175(3):1041-1055. [Epub 2009 Aug 13].
36. Cho S.J., Kang M.J., Homer R.J., Kang H.R., Zhang X., Lee P.J., et al. Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling. J Biol Chem 2006, 281:8161-8168.
37. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet Sep 2004, 5(9):691-701. [Review].
38. Vlad A., Röhrs S., Klein-Hitpass L., Müller O. The first five years of the Wnt targetome. Cell Signal May 2008, 20(5):795-802. [Epub 2007 Nov 17].
39. Selman M., Pardo A., Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs?. PLoS Med Mar 4 2008, 5(3):e62.
40. Königshoff M., Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal?. Am J Respir Cell Mol Biol Jan 2010, 42(1):21-31. [Epub 2009 Mar 27].
41. Bayle J., Fitch J., Jacobsen K., Kumar R., Lafyatis R., Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol Apr 2008, 128(4):871-881.
42. Chilosi M., Poletti V., Zamò A., Lestani M., Montagna L., Piccoli P., et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol May 2003, 162(5):1495-1502.
43. Königshoff M., Kramer M., Balsara N., Wilhelm J., Amarie O.V., Jahn A., et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest Apr 2009, 119(4):772-787.
44. Eckes B., Zigrino P., Kessler D., Holtkotter O., Shephard P., Mauch C., et al. Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 2000, 19:325-332.
45. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., Tamaki K. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 2005, 175:7708-7718.
46. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol 2004, 164:1275-1292.
47. Loeys B.L., Gerber E.E., Riegert-Johnson D., Iqbal S., Whiteman P., McConnell V., et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med 17 March 2010, 2:23ra20. 10.1126/scitranslmed.3000488.
48. Distler J.H., Jüngel A., Pileckyte M., Zwerina J., Michel B.A., Gay R.E., et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum Dec 2007, 56(12):4203-4215.
49. Higgins D.F., Kimura K., Bernhardt W.M., Shrimanker N., Akai Y., Hohenstein B., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest Dec 2007, 117(12):3810-3820.
50. Zhou G., Dada L.A., Wu M., Kelly A., Trejo H., Zhou Q., et al. Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol Dec 2009, 297(6):L1120-L1130.
51. Stockmann C., Kerdiles Y., Nomaksteinsky M., Weidemann A., Takeda N., Doedens A., et al. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci USA Mar 2 2010, 107(9):4329-4334.
52. Huang S.K., Peters-Golden M. Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?. Chest Jun 2008, 133(6):1442-1450. [Review].
53. Oga T., Matsuoka T., Yao C., Nonomura K., Kitaoka S., Sakata D., et al. Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med Dec 2009, 15(12):1426-1430.
54. Tager A.M., LaCamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z., et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med Jan 2008, 14(1):4.
55. Xu M.Y., Porte J., Knox A.J., Weinreb P.H., Maher T.M., Violette S.M., et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol Apr 2009, 174(4):1264-1279.
56. Wei J, Bhattacharyya S., Varga J. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol. 2010, 22(6):671-676.
57. Ghosh A.K., Bhattacharyya S., Lakos G., Chen S.J., Mori Y., Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004, 50:1305-1318.
58. Ghosh A.K., Bhattacharyya S., Wei J., Kim S., Barak Y., Mori Y., et al. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J Sep 2009, 23(9):2968-2977.
59. Ferguson H.E., Kulkarni A., Lehmann G.M., Garcia-Bates T.M., Thatcher T.H., Huxlin K.R., et al. Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol Dec 2009, 41(6):722-730.
60. Chen S.J., Ning H., Ishida W., Sodin-Semrl S., Takagawa S., Mori Y., et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006, 281:21183-21197.
61. Tan X., Dagher H., Hutton C.A., Bourke J.E. Effects of PPARgamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res Feb 23 2010, 11:21.
62. Kapoor M., McCann M., Liu S., Huh K., Denton C.P., Abraham D.J., et al. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum Sep 2009, 60(9):2822-2829.
63. Karnik P., Tekeste Z., McCormick T.S., Gilliam A.C., Price V.H., Cooper K.D., et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol May 2009, 129(5):1243-1257.
64. Kapoor M., Kojima F., Yang L., Crofford L.J. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 2007, 76:103-112.
65. Zheng F., Fornoni A., Elliot S.J., Guan Y., Breyer M.D., Striker L.J., et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol Apr 2002, 282(4):F639-F648.
66. Miyahara T., Schrum L., Rippe R., Xiong S., Yee H.F., Motomura K., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem Nov 17 2000, 275(46):35715-35722.
67. Culver D.A., Barna B.P., Raychaudhuri B., Bonfield T.L., Abraham S., Malur A., et al. Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol Jan 2004, 30(1):1-5.
68. Ye P., Zhang X.J., Wang Z.J., Zhang C. Effect of aging on the expression of peroxisome proliferator-activated receptor gamma and the possible relation to insulin resistance. Gerontology 2006, 52(2):69-75.